ArticleEuropean heart journal. Case reports2026
Association of cardiac sarcoidosis with coronary slow flow: a case report unraveling the enigma.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The exact mechanism of slow coronary flow (SCF) is still not well understood. SCF can manifest as acute coronary syndrome, or in rare scenarios, sudden cardiac death (SCD). Regional microvascular dysfunction (MVD) has been reported in inflammatory cardiomyopathies with a correlation between coronary flow reserve and active myocardial inflammation. Case summary: A 52-year-old gentleman presented with refractory ventricular tachycardia (VT) following an aborted out-of-hospital cardiac arrest. Apart from one prior episode of uninvestigated syncope, there was no history of prior cardiac symptoms or comorbidities. Initial blood tests were unremarkable with a normal troponin level. Coronary angiography identified no obstructive epicardial coronary artery disease but demonstrated SCF that was marked in the right coronary artery (RCA). Subsequent cardiac magnetic resonance imaging demonstrated transmural late gadolinium enhancement in the RCA territory, which correlated to VT origin on the surface electrocardiogram. With no reversible cause of VT identified, an implantable cardioverter defibrillator was implanted for secondary prevention. Following discharge, an out-patient 18F-fluorodeoxyglucose positron emission tomography/computed tomography scan revealed increased metabolic activity suggestive of active inflammatory myocardial involvement, most likely due to cardiac sarcoidosis (CS). Discussion: This case highlights the importance of SCF as a surrogate marker for underlying MVD in relation to active myocardial inflammation. Studies are required to understand the role of MVD as a causal link between SCF and CS. Whether MVD should be considered in risk stratification for primary prevention of SCD in CS patients is to be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.